Skip to main content
. 2024 Oct 9;29(12):1825–1839. doi: 10.1007/s10147-024-02632-x

Fig. 3.

Fig. 3

Fig. 3

Time to response and response duration at long-term follow-up in the total Japanese population receiving A pembrolizumab, B pembrolizumab-chemotherapy, and C EXTREME